- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05269732
CBT for Postpartum Depression and Infant Emotion Regulation
The Impact of Treating Postpartum Depression on Infant Emotion Regulation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L8S 4L8
- McMaster University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- women 18 years of age or older
- understand and speak English (so that they can participate in the CBT group and complete study measures)
- live in Ontario (the primary WHCC catchment area)
- have an EPDS score of 10 or more
- meets diagnostic criteria for comorbid psychiatric conditions.
- Infants must be between 4-12 months old at enrollment.
Exclusion Criteria:
- bipolar disorder
- a current psychotic disorder
- substance or alcohol use disorder
- antisocial or borderline personality disorder.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Control (treatment as usual)
The control group will receive standard postnatal care from their obstetrician, midwife, and/or family physician
|
|
|
Experimental: Treatment (9-week online CBT group)
Participants assigned to the treatment group will continue to receive any healthcare they might already be receiving (e.g.
family doctor, midwife, Obstetrician/Gynecologist, etc.) and participate in a 9-week group Cognitive Behavioral Therapy (CBT) intervention for Postpartum Depression (PPD) delivered via Zoom by two trained psychologists, social workers, nurses, and/or psychiatrists.
|
The 9-week group Cognitive Behavioural Therapy (CBT) intervention for Postpartum Depression (PPD) delivered via Zoom by two trained psychologists.
This intervention was developed by Dr. Van Lieshout (Principal Investigator) at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton.
It was designed to be brief, simple, and applicable to women in community settings.
It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced each week.
The first half of each session is devoted to core CBT content, including cognitive restructuring.
The second half is devoted to group discussions co-led by participants on topics relevant to mothers with PPD (e.g., sleep, supports, role transitions).
Homework is assigned at each session.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Infant Temperament
Time Frame: Enrollment, 9 weeks and 6 months
|
Infant Behavior Questionnaire-Revised (IBQ-R): The IBQ-R is a 91-item scale with 14 subscales that measure infant temperament.
Temperament refers to the ways individuals think, behave, and react and is heavily influenced by the degree to which infants and toddlers can regulate their emotions.
The items on the IBQ ask parents to rate the frequency of specific temperament-related behaviors observed over the past week.
Items are scored on a scale of 0-7.
Mothers will complete the IBQ-R on their infants immediately before treatment, right after treatment (9 weeks), and at 6 months afterward.
|
Enrollment, 9 weeks and 6 months
|
|
Infant emotion regulation
Time Frame: Enrollment, 9 weeks and 6 months
|
Emotional Regulation (ER) is comprised of biological and behavioural domains best measured with validated physiological, observational and informant reports that assess this phenomenon across the full range of infant functioning.
Physiological measures: Medial Pre-frontal complex (mPFC) activity using functional near-infrared spectroscopy will be used to observe infant emotion regulatory patterns.
|
Enrollment, 9 weeks and 6 months
|
|
Maternal Depression
Time Frame: Enrollment, 9 weeks, 6 and 30 months later
|
Edinburgh Postnatal Depression Scale (EPDS): The EPDS is the 10-item gold standard measure of maternal depressive symptoms.
Scores range from 0-30, with higher scores indicating worse depressive symptoms.
Mothers will complete the EPDS immediately before treatment, right after treatment, and at 6 months afterward.
|
Enrollment, 9 weeks, 6 and 30 months later
|
|
Maternal Anxiety
Time Frame: Enrollment, 9 weeks, 6 and 30 months later
|
The Generalized Anxiety Disorder 7-Item Scale (GAD-7) is a self-report scale that taps generalized anxiety disorder, the most common comorbidity of Postpartum Depression (PPD).
Scores range from 0-21 with higher scores indicating worse anxiety symptoms.
Mothers will complete the GAD-7 immediately before treatment, right after treatment, and at 6 months afterward.
|
Enrollment, 9 weeks, 6 and 30 months later
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Brain-to-brain Synchrony (fNIRS)
Time Frame: Enrollment, 9 weeks and 6 months
|
Changes in Mother-Infant Synchrony: Physiological and behavioural synchrony patterns are thought to shape infant ER development and explain how treating PPD may exert its effects on infants.
Brain-to-brain Synchrony (fNIRS): The fNIRS pre-scanning technique will be used.
|
Enrollment, 9 weeks and 6 months
|
|
The Face-to-Face Stillage Paradigm (FFSP)
Time Frame: Enrollment, 9 weeks and 6 months
|
The Face-to-Face Stillage Paradigm (FFSP) will be used to observe infant emotion regulatory patterns.
|
Enrollment, 9 weeks and 6 months
|
|
Parent-Child Early Relational Assessment (PCERA)
Time Frame: Enrollment, 9 weeks and 6 months
|
Parent-Child Early Relational Assessment (PCERA) will be used to observe infant emotion regulatory patterns.
|
Enrollment, 9 weeks and 6 months
|
|
Epigenetic Analyses
Time Frame: Enrollment, 9 weeks and 6 and 30 months later
|
One saliva sample will be taken from infants and from mothers at each study visit will be used for epigenetic analyses.
Epigenetic modifications will be used to mediate and assess the effect of early life interactions on development.
|
Enrollment, 9 weeks and 6 and 30 months later
|
|
mPFC Activity (Dense-array functional near-infrared spectroscopy)
Time Frame: 30 months post T3
|
mPFC Activity (Dense-array functional near-infrared spectroscopy): Measures of oxy- and deoxygenated hemoglobin within the mPFC (medial section of Brodmann areas 9-12 and 25) will be assessed.
Hemodynamic activity generated specifically in the mPFC will be acquired using our Gowerlabs® dense array fNIRS system, which utilizes high density diffuse optical tomography (DOT) to produce 3-D images of targeted brain regions and functional connectivity.
High density-DOT fNIRS technology yields superior temporal and compatible spatial resolution to fMRI, but without needing to examine infants while sedated or asleep.
Adverse mPFC development is one of the most prominent mechanisms underlying later mental disorder risk.
Studies examining fNIRS test-retest and are robust to changes in head size.
In three pilot dyads, it demonstrated exceptional spatial specificity for infant mPFC activity.
|
30 months post T3
|
|
Corticolimbic Brain Activity: Electroencephalographic (EEG) Frontal Alpha Asymmetry (FAA)
Time Frame: 30 months post T3
|
Corticolimbic Brain Activity: Electroencephalographic (EEG) Frontal Alpha Asymmetry (FAA).
Portable EEG headbands provide valid EEG activity assessments in adult and infant populations, and do not interfere with fNIRS caps/recordings.
These headbands will be used to examine asymmetric patterns of EEG activity over the frontal lobes.
These patterns reflect the activity of multiple corticolimbic brain areas underlying affective tendencies and regulatory capacity, including the prefrontal cortex, amygdala, hippocampus, anterior cingulate and insula.
Greater relative right FAA in infancy reflects a predisposition to negative emotions and difficulties regulating them, is considered a marker of psychopathology vulnerability and is linked to increased risk for depression and anxiety across the lifespan.
Measures of FAA are stable across infancy and into childhood.
|
30 months post T3
|
|
PSNS Activity: High-frequency Heart Rate Variability (HF-HRV)
Time Frame: 30 months post T3
|
PSNS Activity: High-frequency Heart Rate Variability (HF-HRV).
HF-HRV, obtained by the Mindware LTD electrocardiogram (ECG), reflects greater flexibility of the PSNS to handle stress and enables infants to utilize social interactions to regulate physiological states.
HRV is linked to the integrated activity of multiple brain regions, including the mPFC and amygdala.
HRV is an index of coordinated activity in top-down regulatory brain regions and sub-cortical emotion generation networks that serve to guide flexible, adaptive control of behaviour.
Low HRV in infancy is among the earliest emerging markers of poor ER and is linked to risk for depression, anxiety and even physical health problems in adulthood.
HF-HRV shows robust test-retest reliability across infancy.
|
30 months post T3
|
|
Dyadic regulation of frustration
Time Frame: 30 months post T3
|
Parent-Child Play Task: Birthing parents and their child will be given a 3D puzzle comprised of 7 wooden pieces of different lengths and colours (Castle Logix, Smart Games).
The puzzle can be solved in different ways based on a guidebook.
Parents will be given the guidebook and asked to instruct the child (using only their words) to design two versions of the puzzle.
This task aims to challenge the dyad through a problem solving situation, and assesses dyadic regulation of frustration.
The dyad will play with this activity for 5 minutes.
|
30 months post T3
|
|
Frustration and flexible attention regulation
Time Frame: 30 months post T3
|
Tower of Patience task: This task will be used to measure frustration and flexible attention regulation.
The child and the tester (research assistant) will work together to build a tower out of blocks.
They will take turns placing blocks on top of one another.
Each time it is the tester's turn to place a block, they will delay their turn by intervals of 10 seconds (i.e., wait 10 seconds to place block one, wait 20 seconds to place block two, wait 30 seconds to place block three, and so on until 8 blocks have been placed or 4 turns have passed).
|
30 months post T3
|
|
Higher-order flexibility capacity
Time Frame: 30 months post T3
|
Pet-Store Stroop Task: Using a touch screen computer, children are tasked with putting animals which had escaped from a pet store back into their cages (bring a dog back to the other dogs).
In control conditions, animals are identified by both their appearance and sound (a dog will bark).
However, in conditions designed to assess neurobehavioural flexibility, animals will utter the sound of a different species (a dog will say "meow")- and children are required to sort the animal based on the sound, not appearance.
This task is sensitive to early emerging higher-order flexibility capacity (shifting attention between competing demands) and activates the PFC brain regions that appear to be affected by exposure to PPD, and that underly ER2.
The task takes approximately 5 minutes to complete.
|
30 months post T3
|
|
Child Temperament
Time Frame: 30 months post T3
|
Child behavior Questionnaire Very Short Form (CBQ-VSF): Birthing parents will complete the 36-item CBQ-VSF, which captures three broad dimensions of child temperament, each of which contribute to ER capacity.
|
30 months post T3
|
|
Irritability Behaviours
Time Frame: 30 months post T3
|
Multidimensional Assessment Profile Temper Loss (MAPS-TL) Scale: Children's mothers will complete the 22-item Temper Loss Scale of the MAP, which uses a Likert-Type Scale (never=0, many times per day=6) to assess the intensity and duration of key irritability behaviours, including mood and tantrums (e.g., "gets quite frustrated when prevented from doing something s/he wants to do").
Importantly, this scale is specifically designed to decipher between typical and atypical levels of irritability in early childhood.
|
30 months post T3
|
|
Child Emotion Regulation
Time Frame: 30 months post T3
|
Child Behavior Questionnaire (CBCL 1.5-5):
The CBCL is a validated, well recognized scale which measures multiple problem behaviours associated with poor ER capacity.
Birthing parents will complete this 99-item scale to assess these potential problem behaviours in their child4.
|
30 months post T3
|
|
Mechanisms underlying changes to infant ER
Time Frame: 30 months post T3
|
Changes in Mother-Infant Synchrony Brain-to-brain Synchrony (fNIRS): We will use fNIRS hyperscanning techniques to target synchronized right dorsolateral (Brodmann's area 9 and 46) and frontopolar activity (Brodmann's area 10) of the PFC within dyads. Frontal EEG Asymmetry Synchrony PSNS Synchrony Behavioural Synchrony will be quantified by examining the duration of mismatched emotions and behaviours within dyads during the FFSP paradigm during the free play task at T4. Maternal Regulatory Parenting: At T4, regulatory parenting (appropriate limit setting, resourcefulness) will be examined using the coding interactive behaviour (CIB) scale during the free play task |
30 months post T3
|
|
Maternal Emotion Regulation
Time Frame: 30 months post T3
|
Maternal Emotion Regulation: At T4, the Difficulties in Emotion Regulation Scale (DERS) will be used to assess emotion regulation in mothers.
This is a 36-item self-report measure that assesses one's ability to understand, accept, and manage their emotions.
It assesses difficulties in six areas of emotion regulatory capacity in adults: non-acceptance of negative emotions, inability to engage in goal-directed behaviors when distressed, difficulties with impulse control, lack of awareness of emotional responses, limited access to regulation strategies, and difficulty understanding and clarifying.
|
30 months post T3
|
|
Diagnostic Assessment Research Tool
Time Frame: 30 months post T3
|
The DART will be used to determine probable diagnosis of MDD and GAD.
|
30 months post T3
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
NEO-FFI: the NEO Five-Factor Inventory
Time Frame: 30 months post T3
|
NEO-FFI is a self-report questionnaire that assesses an individual's personality.
It is based on the five-factor model of personality (Openness to Experience, Conscientiousness, Extraversion, Agreeableness, and Neuroticism), and consists of 60 items.
|
30 months post T3
|
|
Maternal Mood Variability
Time Frame: 30 months post T4
|
Maternal Mood Variability: Questionnaire of unpredictability in childhood-brief-QUIC-5 will be used to capture unpredictable experiences in the mother's own childhood.
|
30 months post T4
|
|
Maternal Sleep
Time Frame: 30 months post T3
|
Maternal Sleep: Sleep disturbances are common during the peripartum, and have adverse effects on maternal mood, behaviour and mother-infant interactions.
Therefore, the Insomnia Symptom Questionnaire (ISQ) will be used to assess maternal insomnia symptoms, and overall sleep quality.
|
30 months post T3
|
|
Maternal Sleep Quality
Time Frame: 30 months post T3
|
Maternal Sleep: Sleep disturbances are common during the peripartum, and have adverse effects on maternal mood, behaviour and mother-infant interactions.
Therefore, the Pittsburgh Sleep Quality Index (PSQI) will be used to assess maternal insomnia symptoms, and overall sleep quality.
|
30 months post T3
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ryan Van Lieshout, MD, PHD, Mcmaster
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PIER CBT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.